Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Jumped Today

By Keith Speights - Apr 15, 2021 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered good news from the company's COVID-19 vaccine partner.

What happened

Shares of Dynavax Technologies (DVAX 2.94%) were jumping 7.1% higher as of 3:38 p.m. EDT on Thursday. The gain came after Valneva reported positive initial results from the first part of a phase 1/2 clinical study evaluating its COVID-19 vaccine candidate VLA2001. This experimental vaccine uses Dynavax's CpG 1018 adjuvant.

So what

Valneva tested three doses of VLA2001 in the phase 1/2 study. The company reported especially encouraging results for the high dose of its COVID-19 vaccine candidate. All participants in the study who received the high dose developed significant levels of IgG antibodies to the SARS-CoV-2 virus spike protein.

Hand holding vaccine vial and syringe with scientists and a microscope in the background

Image source: Getty Images.

Dynavax's CpG 1018 adjuvant almost certainly played a key role in those great results. CEO Ryan Spencer said, "We are excited to see the positive results Valneva has generated with their inactivated vaccine using Dynavax's CpG 1018 adjuvant." He added, "We believe the effect delivered by our CpG 1018 adjuvant combined with Valneva's existing manufacturing process for whole virus inactivated vaccines will result in an important option in the global fight against COVID-19."

Now what

Valneva now plans to advance its COVID-19 vaccine into a pivotal late-stage clinical study by the end of this month, pending regulatory approval. This could bode well for Dynavax. Positive results from the late-stage study would provide an even bigger catalyst for the biotech stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$12.96 (2.94%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.